EC designates liposomal daunorubicin as orphan product for AML treatment
The EC has designated Galen's liposomal daunorubicin as an orphan medicinal product for the treatment of acute myeloid leukaemia (AML). Liposomal daunorubicin is currently approved in a number of European countries, the US and Brazil for the treatment of advanced HIV-related Kaposi's sarcoma, as the medicinal product, DaunoXome.
This anthracycline chemotherapy agent works by attacking cancer cells and interfering with DNA production, which stops cancer cells from multiplying. The product has a different delivery system compared with conventional anthracyclines; it has a type of liposomal coating and particle size, which enables it to effectively target malignant tumours.
Galen acquired the product from Gilead Sciences earlier in 2012.